Trials / Completed
CompletedNCT00236067
A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Gabitril(up to 16 mg/Day) in the Treatment of Adults With Generalized Anxiety Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 440 (planned)
- Sponsor
- Cephalon · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gabitril |
Timeline
- Start date
- 2004-10-01
- Completion
- 2006-03-01
- First posted
- 2005-10-12
- Last updated
- 2014-05-09
Locations
21 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00236067. Inclusion in this directory is not an endorsement.